Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

rial with the general applicability of a 'real-world' study, since it included all patients at our clinic who initiated hepatitis C treatment and met basic eligibility criteria," said Professor Colombo. "The results from this study prove that treatment success rates in the real world can be comparable to those achieved in clinical trials. The study also demonstrates that PEGASYS regimens enable significantly more patients to achieve a SVR."

PEGASYS has demonstrated efficacy in a broad range of patient types, even those with poor prognostic factors.(2)(3)(4)(5)(6)

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), is indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chroni
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Services, Inc. (NYSE: WST ) today announced ... the first-quarter 2010 cash dividend of $0.16 per share. ... to shareholders of record on January 20, 2010. ... global manufacturer of components and systems for injectable drug ... and disposable components used in syringe, IV and blood ...
(Date:12/15/2009)... Del., Dec. 15 The U.S. Food and ... (EMDAC) today voted 12 yes, 4 no, and 1 ... the observed risks to support the use of CRESTOR® ... Men greater than or equal to 50 years, ... Fasting LDL < 130 mg/dL; hsCRP greater than ...
(Date:12/15/2009)... SRI International, an independent nonprofit research and development ... 7,592,021 for a new bioadhesive drug delivery system ... human body,s mucous membranes. This needle-free option uses ... much longer release time compared to alternatives such ... an effective means to introduce drugs across the ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Are intravenous treatments safe 3F New research raises doubts 55731 1Are intravenous treatments safe 3F New research raises doubts 55731 2Open source DNA 55727 1New developments in reproductive medicine 9741 1New developments in reproductive medicine 9741 2
... Biotechnologies,announced today the results of Phase I/II and ... sarcoma and osteosarcoma, as,presented by Dr. Sant P. ... held in London UK on November 13-15, 2008. ... period up to 9 months. Analysis of,safety and ...
... PHILADELPHIA, Nov. 20 GlaxoSmithKline (NYSE: GSK ... and Drug Administration (FDA) granted accelerated approval for ... patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) ... immunoglobulins or splenectomy. The approval is a significant ...
Other Medicine Technology:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8
(Date:12/16/2009)... of hearing aids has been brought into reach for many Houstonians ... based hearing plan. , ... (PRWEB) December 16, 2009 ... for many Houstonians with the announcement by Hearing Haven, LLC of ... hearing better on the job, and want to improve communications and ...
(Date:12/16/2009)... Ltd. is proud to announce being presented with the Weatherhead 100 ... the fastest growing companies in Northeast Ohio and is a testament ... , ... (PRWEB) December 16, 2009 -- ... the Weatherhead 100 Upstart Award on December 3, 2009. The ...
(Date:12/16/2009)... development of products that help survivors of stroke and other ... publication of an interview with the inventors of their brand ... Therapy and Rehab Medicine, vol. 20, issue 20, page 26, ... ... (PRWEB) December 16, 2009 -- In the publication, ...
(Date:12/16/2009)... will continue to offer free nationwide confidential legal consultations for ... effects such as: Birth Defects, Attempted Suicide, Suicide and Addiction ... free at 1-800-856-6405 or go to the firm’s website at ... form. , ... (PRWEB) December 16, ...
(Date:12/16/2009)... carrying Dr. Shapio,s Help Hair Shake in all of the Florida Whole ... ... 2009 -- Dr. Larry Shapiro, hair transplant and hair loss ... be carrying the Help Hair Whey Protein Shake. Dr. Shapiro developed ... adjunct for weight loss programs, working out and muscle building., , , ...
Breaking Medicine News(10 mins):Health News:Monthly Subscription Hearing Aid Plan Announced for Houston 2Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2
... gay governor, James E. McGreevy appears to be knocking on ... in the news// for the right reasons. He has been ... ,Former Gov. James E. McGreevy, who was brought up as ... on Sunday at St. Bartholomew's Church in New York. He ...
... units in UK is an eye-opener to prevailing malfunctions which ... a sting operation conducted by BBC, some maternity units came ... ,Some of the maternity units were facing an acute shortage ... work. The midwife in charge at a hospital where the ...
... survival has improved over time. However, for recipients with ... in the issue of Liver Transplantation. ,HCV-induced ... transplantation in the U.S., however, previous studies have shown ... liver transplantation. The difference has become even more striking ...
... States the gays prefer to find out whether their partner’s ... use protection to prevent// catching the disease. The risky behavior ... virus, which is on the rise. ,In Britain, ... virus and they continue to have unprotected sex. The saliva ...
... contaminated feed is causing concern among the people. The consumption of ... FDA is quick to play down the fear saying that it ... to light after some 38 chicken farms in Indiana was investigated ... chicken for human consumption with the contaminated feed. Until the investigation ...
... and the good fats in Omega-3 fatty acids help new ... the issue// of the International Breastfeeding Journal. ... anywhere from 10 percent to 20 percent of postpartum women. ... high as 40 percent or 50 percent. Since depression has ...
Other Medicine News:Health News:United Kingdom: Maternity Units Exposed! Leaves Much to Be Desired 2Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2Health News:Unprotected Sex Among the Gays on the Rise 2Health News:Tainted Pet Food a Health Risk for Human? 2Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2
Four 62 mirrors give a 360 view of the anterior chamber angle with only a slight lens rotation. Posterior pole can be viewed through center of lens....
Two opposing 62 mirrors provide a complete view of the anterior chamber angle with only a 180 lens rotation. Methylcellulose and no methylcellulose designs available....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Medicine Products: